Abstract: The present invention relates to novel boron comprising compounds, to pharmaceutical compositions comprising said compounds, to the therapeutic use of said compounds, and to a process for preparation of said compounds. The compounds are useful in boron neutron capture therapy (BNCT).

Abstract: The present invention relates to novel boron comprising compounds, to pharmaceutical compositions comprising said compounds, to the therapeutic use of said compounds, and to a process for preparation of said compounds. The compounds are useful in boron neutron capture therapy (BNCT).

Abstract: A device and a method for spraying a certain quantity of fluid. The device includes a casing with a cavity for accommodating a liquid reservoir and a pump which delivers a specific quantity fluid upon activation. The device further includes a nozzle through which the flow of fluid passes in the form of spray droplets together with an activating device which acts upon the base of the reservoir due to the application of opposing forces to the casing, basically at right angles to the pumping movement of the device.

Abstract: The present invention relates to a new use of certain pharmaceutically active compounds in the treatment and/or prevention of medicament induced gastric ulcer. More particularly the invention is directed to the use of said compounds, and pharmaceutically acceptable salts thereof, for the treatment and/or prevention of NSAID (non-steroidal antiinflammatory drugs) induced gastric ulcer as well as a pharmaceutical composition in the unit dosage form for the prevention of NSAID induced gastric ulcer in a mammal comprising an NSAID together with a 6-carboxamido-imidazo[1,2-a]pyridine compounds. Other pharmaceutically active compounds used in the present invention comprises COX-2 inhibitors, NO-NSAIDs and bisphosphonates.

Abstract: The present invention relates to a new use of certain pharmaceutically active compounds in the treatment and/or prevention of medicament induced gastric ulcer. More particularly the invention is directed to the use of said compounds, and pharmaceutically acceptable salts thereof, for the treatment and/or prevention of NSAID (non-steroidal antiinflammatory drugs) induced gastric ulcer as well as a pharmaceutical composition in the unit dosage form for the prevention of NSAID induced gastric ulcer in a mammal comprising an NSAID together with a 6-carboxamido-imidazo[1,2-a]pyridine compounds. Other pharmaceutically active compounds used in the present invention comprises COX-2 inhibitors, NO-NSAIDs and bisphosphonates.

Abstract: 1

Abstract: The present invention relates to novel compounds of Formula I, and pharmaceutically acceptable salts thereof, as antibacterial agents. The compounds of the present invention are nitric oxide releasing derivatives of proton pump inhibitors (NO-releasing PPIs). In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above. The invention also relates to new intermediates for use in the preparation of the novel compounds. Additionally the present invention relates to co-administration of NO-releasing PPIs with other known medicaments.

Abstract: A closure device is designed for attachment on a neck portion (1) of a separate container (2), preferably of glass material, which holds a first substance. The closure device defines a passage (10) extending between opposite first and second openings (11, 13) of the closure device. A sealing means (30) is arranged to close off the first opening (11) and confine a second substance in the passage (10). A penetration means (33) is incorporated in the device and operable to penetrate the sealing means (30) such that fluid communication is established between the passage (10) and the container (2). In a method of mixing the first and second substances, a medical practitioner exposes the second opening (13) by removing a non-resealable cap (8), by introducing and engaging the end of a syringe directly in the second opening (13), and by operating the penetration means (33) to penetrate the sealing means (30).

Abstract: The present invention discloses a new use of NO-releasing NSAIDs, especially NO-releasing NSAIDs of the formula I, or a pharmaceutically acceptable salt or enantiomer thereof, for the manufacture of a medicament for the treatment of bacterial infections, especially caused or mediated by Helicobacter pylon. Disclosed is also the new use of a NO-releasing NSAID in combination with an acid susceptible proton pump inhibitor for the treatment of bacterial infections.

Abstract: The present invention relates to novel compounds of Formula I, and pharmaceutically acceptable salts thereof, as antibacterial agents. The compounds of the present invention are nitric oxide releasing derivatives of proton pump inhibitors (NO-releasing PPIs). In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above. The invention also relates to new intermediates for use in the preparation of the novel compounds. Additionally the present invention relates to co-administration of NO-releasing PPIs with other known medicaments.

Abstract: The invention relates to a method of managing septic shock and counteracting endotoxin induced deterioration of arterial oxygen tension which comprises administration of an effective amount of a sterile pharmaceutical composition for parenteral administration, which composition comprises the compound 2,6-diisopropylphenol (propofol) in association with a sterile pharmaceutically-acceptable diluent or carrier, and the use of such a sterile pharmaceutical composition for use as a medicament for managing septic shock, and the use of such a sterile pharmaceutical composition for the manufacture of a medicament for the management of septic shock and for counteracting endotoxin induced deterioration of arterial oxygen tension.

Abstract: Medical device (1) for effecting heat treatment and local delivery of a fluid medicament on body tissue presenting a predetermined section of a boundary wall of a passageway in a human or animal body comprising a catheter-like member (12) for insertion into the passageway to a predetermined insertion position, the catheter-like member being provided with an inflatable balloon structure (11) having a boundary wall which is inflatable against the body tissue when the catheter-like member (12) is in the predetermined insertion position and delivery means (2,11,25) for local delivery of the fluid medicament on the body tissue when the catheter-like member (12) is in the predetermined insertion position, and a heating arrangement (10,15) which is adapted to heat the body tissue when the catheter-like member (12) is in the predetermined insertion position.

Abstract: A delivery means for delivering liquid containing medicament to a posterior region of the nasal cavity, comprising an elongate tubular member (35; 151) and a nozzle (37; 153) at the free end thereof, which nozzle (37; 153) includes at least one opening (39; 155) through which liquid is in use delivered.

Abstract: The present invention relates to a pump chamber (1) for a pump intended primarily for infusion systems for medical use, said pump chamber comprising walls (21, 28) delimiting said chamber and an inlet (22) and an outlet (23), a part of said walls of said pump chamber being formed by a flexible membrane (40, 90), said membrane being actuatable by a reciprocally movable actuating means (80), thus varying the volume of the pump chamber in accordance with the movements of said actuating means. The membrane (40, 90) has a convex domed shape projecting outwardly from said pump chamber (1) and is made of a resiliently flexible material, the apex of the domed membrane being acted upon by said actuating means, said actuating means having a stroke which may be adjusted to the amount of the dose to be administered. The invention also relates to a valve for a pump chamber.

Abstract: New combination of a .beta.-receptor blocker or a pharmaceutically acceptable salt thereof, and an opioid or a pharmaceutically acceptable salt thereof, optionally in the presence of a pharmaceutically acceptable carrier or any additional agents which may be active or inactive. The new combination confers a synergistic effect, and provides unexpected efficacy in the treatment of pain.

Abstract: New combination of a .beta.-receptor blocker, an enantiomer thereof, and a local anesthetic, administered simultaneously or sequentially, giving excellent pain relief. Also comprised in the invention is the use of a non-selective .beta.-receptor blocker alone, especially a non-selective .beta.-receptor blocker giving pain relief.